Physician profile
James L Ray
NPI 1679523419
$1,684.71
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $303 · 2021: $491 · 2022: $215 · 2023: $220 · 2024: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $425.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $239.42 | 2021-2024 | |
| Novo Nordisk INC | $153.47 | 2019-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $145.03 | 2019-2024 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $133.11 | 2019-2024 | Airsupra, Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $101.46 | 2019-2023 | |
| Allergan, INC. | $97.18 | 2019-2020 | |
| Daiichi Sankyo INC. | $78.88 | 2019-2023 | Injectafer |
| Glaxosmithkline, LLC. | $76.68 | 2019-2023 | Trelegy Ellipta |
| Pfizer INC. | $75.08 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $70.67 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $68.35 | 2019-2024 | Verquvo |
| Takeda Pharmaceuticals U.S.A., INC. | $55.90 | 2020 | |
| Biogen, INC. | $55.35 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $54.54 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $50.96 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $50.04 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.57 | 2021 | |
| Alkermes, INC. | $27.79 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $24.39 | 2021 | |
| Indivior INC. | $18.30 | 2020 | |
| Exact Sciences Corporation | $17.28 | 2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $15.92 | 2021 | |
| Amgen INC. | $13.14 | 2024 | Repatha |
| Eisai INC. | $13.02 | 2020 | |
| Shire North American Group INC | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.